Zacks Research Has Bullish Outlook for HALO FY2025 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a note issued to investors on Monday, February 2nd. Zacks Research analyst Team now expects that the biopharmaceutical company will earn $6.01 per share for the year, up from their prior forecast of $5.91. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.86 EPS, Q1 2026 earnings at $1.42 EPS, Q2 2026 earnings at $1.80 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at $2.38 EPS, FY2026 earnings at $7.43 EPS, Q2 2027 earnings at $2.02 EPS, Q3 2027 earnings at $1.99 EPS, Q4 2027 earnings at $2.54 EPS and FY2027 earnings at $8.18 EPS.

Several other equities analysts have also weighed in on the stock. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $78.80.

Halozyme Therapeutics Trading Up 2.7%

Shares of HALO stock opened at $76.48 on Wednesday. The stock has a 50-day simple moving average of $69.01 and a 200 day simple moving average of $68.78. The stock has a market capitalization of $8.99 billion, a P/E ratio of 16.10, a P/E/G ratio of 0.32 and a beta of 0.97. Halozyme Therapeutics has a fifty-two week low of $47.50 and a fifty-two week high of $79.50. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same period last year, the firm earned $1.27 EPS.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 16,569 shares of Halozyme Therapeutics stock in a transaction on Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the transaction, the chief executive officer owned 708,719 shares in the company, valued at $48,844,913.48. This represents a 2.28% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 41,398 shares of company stock valued at $2,861,352. 2.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of HALO. DLD Asset Management LP purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $650,250,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Halozyme Therapeutics by 127.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after purchasing an additional 1,425,674 shares during the period. Federated Hermes Inc. grew its position in Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after purchasing an additional 1,082,638 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at approximately $77,587,000. Finally, Qube Research & Technologies Ltd purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $51,295,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple near‑term and multi‑year EPS forecasts for HALO — highlights include Q1 2026 to $1.42 (from $1.19), Q2 2026 to $1.80 (from $1.49), Q3 2026 to $1.83 (from $1.70), Q4 2026 to $2.38 (from $1.84), FY2026 to $7.43 (from $6.22), and FY2027 to $8.18 (from $7.57). These larger upward revisions suggest Zacks expects stronger partner/license revenues and continued margin leverage.
• Positive Sentiment: Zacks also lifted several individual quarter forecasts for 2027 (Q2 2027 to $2.02 and Q4 2027 to $2.54), reinforcing the firm’s view of sustained earnings growth beyond 2026.
• Positive Sentiment: Analysis arguing Halozyme’s acquisitions could drive long‑term growth, which supports a bullish investment thesis around expanding revenue streams and optionality. Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth
• Neutral Sentiment: A Zacks preview piece highlights Halozyme’s strong history of earnings surprises and argues the company has the mix of factors that could produce another beat — supportive but not a concrete catalyst by itself. Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
• Negative Sentiment: One small downward tweak from Zacks: Q3 2027 EPS was trimmed slightly to $1.99 from $2.02 — a marginal cut that is unlikely to outweigh the larger, company‑wide upward revisions but technically negative.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.